Patient Surveillance After Cancer Treatment covers the history of cancer patient surveillance after curative-intent treatment, the rationale, the methodologies used in the past and at present, the methodologies that will probably emerge in the future, the costs of surveillance, the definitions of various terms used in the field, and how those who are interested in the topic can get more information about it from the internet. The secondary focus of the book is to publicize the need for well-designed, adequately powered randomized clinical trials comparing two (or more) surveillance strategies for each type of cancer.
The audience includes all oncologists, cancer researchers, medical economists and policy makers in government and insurance companies, and finally, interested patients.
This book is part of the Current Clinical Oncology series, which provides cutting-edge knowledge of cancer diagnosis, management, and treatment. World renowned experts share their insights in all the major fields of clinical oncology. From the fundamentals of pathophysiology to the latest developments in experimental and novel therapies, Current Clinical Oncology is an indispensable resource for today's practicing oncologist.
Dr. Frank E. Johnson, MD
1. Overview
David Y. Johnson and Frank E. Johnson
2. Introduction to Cancer Surveillance Strategies
Brooke Crawford and David D. Greenberg
3. Using Decision Analysis to Model Cancer Surveillance
Kim E.M. van Kessel, Sandra M.E. Geurts, André L.M. Verbeek, and Ewout W. Steyerberg
4. Cancer Survivorship: Monitoring the Long-Term and Late Effects of Treatment
Craig C. Earle and Jennifer Deevy
5. Upper Aerodigestive Tract Carcinoma
David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson
6. Upper Aerodigestive Tract Carcinoma Surveillance Counterpoint: Europe
Béatrix Barry and Dominique De Raucourt
7. Upper Aerodigestive Tract Carcinoma Surveillance Counterpoint: Japan
Torahiko Nakashima, Ryuji Yasumatsu, and Shizuo Komune
8. Upper Aerodigestive Tract Carcinoma Surveillance Counterpoint: Canada
Richard W. Nason and James B. Butler
9. Thyroid (Papillary, Follicular, Medullary, Hürthle Cell) Carcinoma
David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson
10. Thyroid (Papillary, Follicular, Medullary, Hürthle Cell) Carcinoma Surveillance Counterpoint: Australia
Leigh Delbridge
11. Thyroid (Papillary, Follicular, Medullary, Hürthle Cell) Carcinoma Surveillance Counterpoint: Japan
Ryuji Yasumatsu, Torahiko Nakashima, and Shizuo Komune
12. Lung Carcinoma
Shilpi Wadhwa, David Y. Johnson, and Frank E. Johnson
13. Lung Carcinoma Surveillance Counterpoint: Australia
Michael Boyer and Kate Mahon
14. Lung Carcinoma Surveillance Counterpoint: Japan
Tokujiro Yano and Yoshihiko Maehara
15. Lung Carcinoma Surveillance Counterpoint: Canada
Gail Darling, Yee Ung, Peter Ellis, Lorraine Martelli-Reid, and Bill Evans
16. Esophagus Carcinoma
Shilpi Wadhwa, David Y. Johnson, and Frank E. Johnson
17. Esophagus Carcinoma Surveillance Counterpoint: Australia
Bernard Mark Smithers, Janine M. Thomas, and Bryan H. Burmeister
18. Esophagus Carcinoma Surveillance Counterpoint: Japan
Masaru Morita and Yoshihiko Maehara
19. Stomach
Shilpi Wadhwa, David Y. Johnson, and Frank E. Johnson
20. Stomach Carcinoma Surveillance Counterpoint: USA
Andrew Coleman and Douglas Tyler
21. Stomach Carcinoma Surveillance Counterpoint: Japan
Yoshihiro Kakeji, Masaru Morita, and Yoshihiko Maehara
22. Pancreatic Adenocarcinoma
David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson
23. Pancreatic Adenocarcinoma Surveillance Counterpoint: USA
Tanios S. Bekaii-Saab
24. Pancreatic Adenocarcinoma Surveillance Counterpoint: Europe
Richard A. Smith, Jane V. Butler, and John P. Neoptolemos
25. Pancreatic Adenocarcinoma Surveillance Counterpoint: Japan
Ken Shirabe and Yoshihiko Maehara
26. Pancreatic Adenocarcinoma Surveillance Counterpoint: Canada
Malcolm J. Moore and Anastasios Stathis
27. Liver and Biliary Tract Carcinoma
David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson
28. Liver and Biliary Tract Carcinoma Surveillance Counterpoint: Europe
Michele Colledan
29. Liver and Biliary Tract Carcinoma Surveillance Counterpoint: Australia
Michael D. Crawford
30. Liver and Biliary Tract Carcinoma Surveillance Counterpoint: Japan
Akinobu Taketomi and Yoshihiko Maehara
31. Liver and Biliary Tract Carcinoma Surveillance Counterpoint: Canada
Oliver F. Bathe and Kelly Warren Burak
32. Colon and Rectum Carcinoma
David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson
33. Colon and Rectum Carcinoma Surveillance Counterpoint: USA
Mohamedtaki A. Tejani and Steven J. Cohen
34. Colon and Rectum Carcinoma Surveillance Counterpoint: Australia
Toufic El-Khoury, Michael Solomon, and Jane Young
35. Colon and Rectum Carcinoma Surveillance Counterpoint: Japan
Yasushi Toh and Yoshihisa Sakaguchi
36. Colon and Rectum Carcinoma Surveillance Counterpoint: Canada
Marko Simunovic
37. Anal Carcinoma
David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson
38. Anal Carcinoma Surveillance Counterpoint: USA
Jonathan M. Hernandez, Erin M. Siegel, Abby Koch, and David Shibata
39. Anal Carcinoma Surveillance Counterpoint: Australia
Toufic El-Khoury, Michael Solomon, and Jane Young
40. Anal Carcinoma Surveillance Counterpoint: Japan
Yoshihisa Sakaguchi and Yasushi Toh
41. Anal Carcinoma Surveillance Counterpoint: Canada
Natasha Press and John Hay
42. Soft Tissue Sarcoma
David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson
43. Soft Tissue Sarcoma Surveillance Counterpoint: USA
Valeriy Sedov and Janice M. Mehnert
44. Soft-Tissue Sarcoma Surveillance Counterpoint: Japan
Shuichi Matsuda and Yukihide Iwamoto
45. Soft Tissue Sarcoma Surveillance Counterpoint: Canada
Lloyd A. Mack and Vivien H.C. Bramwell
46. Osteogenic Sarcoma and Dedifferentiated Chondrosarcoma
David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson
47. Osteogenic Sarcoma and Dedifferentiated Chondrosarcoma Surveillance Counterpoint: Japan
Shuichi Matsuda and Yukihide Iwamoto
48. Osteogenic Sarcoma and Dedifferentiated Chondrosarcoma Surveillance Counterpoint: Canada
Timothy R. Asmis, Joel Werier, and Shailendra Verma
49. Cutaneous Melanoma
David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson
50. Cutaneous Melanoma Surveillance Counterpoint: USA
Gerald Linette and Lynn A. Cornelius
51. Cutaneous Melanoma Surveillance Counterpoint: Australia
Michael A. Henderson
52. Cutaneous Melanoma Surveillance Counterpoint: Japan
Yoichi Moroi
53. Breast Carcinoma
David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson
54. Breast Carcinoma Surveillance Counterpoint: USA
Kelli Pettit and Julie A. Margenthaler
55. Breast Carcinoma Surveillance Counterpoint: Europe
Stefano Ciatto
56. Breast Carcinoma Surveillance Counterpoint: Australia
Andrew J. Spillane and Meagan E. Brennan
57. Breast Carcinoma Surveillance Counterpoint: Japan
Eriko Tokunaga and Yoshihiko Maehara
58. Endometrial Carcinoma
David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson
59. Endometrial Cancer Surveillance Counterpoint: USA
Amit Bhate, Eric Donnelly, John Lurain, Julian Schink, and William Small Jr.
60. Endometrial Cancer Surveillance Counterpoint: USA
Summer B. Dewdney and Premal H. Thaker
61. Carcinoma of the Endometrium Surveillance Counterpoint: Japan
Yousuke Ueoka, Hiroaki Kobayashi, and Norio Wake
62. Endometrial Carcinoma Surveillance Counterpoint: Canada
Michael Fung-Kee-Fung and Thomas K. Oliver
63. Cervical Carcinoma
David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson
64. Cervical Carcinoma Surveillance Counterpoint: USA
Joshua P. Kesterson and Shashikant Lele
65. Cervical Carcinoma Surveillance Counterpoint: Japan
Kenzo Sonoda, Hiroaki Kobayashi, and Norio Wake
66. Cervical Carcinoma Surveillance Counterpoint: Canada
Michael Fung-Kee-Fung and Thomas K. Oliver
67. Vaginal and Vulvar Carcinoma
David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson
68. Vaginal and Vulvar Carcinoma Surveillance Counterpoint: Japan
Shinji Ogawa, Hiroaki Kobayashi, and Norio Wake
69. Ovarian Carcinoma
David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson
70. Ovarian Carcinoma Surveillance Counterpoint: USA
Maurie Markman
71. Ovarian Cancer Surveillance Counterpoint: Europe
Andy Nordin
72. Ovarian Cancer Surveillance Counterpoint: Japan
Hiroaki Kobayashi and Norio Wake
73. Renal Carcinoma
Shilpi Wadhwa, David Y. Johnson, and Frank E. Johnson
74. Renal Carcinoma Surveillance Counterpoint: Europe
Alessandro Antonelli, Claudio Simeone, and Sergio Cosciani Cunico
75. Renal Carcinoma Surveillance Counterpoint: Japan
Masatoshi Eto, Wataru Takahashi, Yoshiaki Kawano, Jiro Honda, Juro Nakanishi, and Yoshihiro Wada
76. Renal Carcinoma Surveillance Counterpoint: Canada
Michael Leveridge, Robert Abouassaly, and Michael A.S. Jewett
77. Urinary Bladder Carcinoma
David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson
78. Urinary Bladder Carcinoma Surveillance Counterpoint: Japan
Kentaro Kuroiwa
79. Urinary Bladder Carcinoma Surveillance Counterpoint: Canada
Faysal A. Yafi and Wassim Kassouf
80. Prostate Carcinoma
David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson
81. Prostate Carcinoma Surveillance Counterpoint: USA
Angela Smith and Raj Pruthi
82. Prostate Carcinoma Surveillance Counterpoint: USA
Erik T. Goluboff and Matthew Wosnitzer
83. Prostate Carcinoma Surveillance Counterpoint: Europe
Stefano Ciatto
84. Prostate Carcinoma Surveillance Counterpoint: Japan
Akira Yokomizo
85. Prostate Carcinoma Surveillance Counterpoint: Canada
Andrew Loblaw and Colin Tang
86. Testicle Carcinoma
David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson
87. Testicle Carcinoma Surveillance Counterpoint: USA
Ian M. Thompson III and Sam S. Chang
88. Testicle Carcinoma Surveillance Counterpoint: Australia
Michael Boyer and Kate Mahon
89. Testicle Carcinoma Surveillance Counterpoint: Japan
Narihito Seki
90. Lymphoma
David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson
91. Lymphoma Surveillance Counterpoint: USA
Kenneth R. Carson and Nancy L. Bartlett
92. Lymphoma Surveillance Counterpoint: Japan
Kenjiro Kamezaki
93. Lymphoma (Following Autologous Stem Cell Transplant)
Shilpi Wadhwa, David Y. Johnson, and Frank E. Johnson
94. Lymphoma (Following Autologous Stem Cell Transplant) Surveillance Counterpoint: Japan
Toshihiro Miyamoto
95. Leukemia
David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson
96. Leukemia Surveillance Counterpoint: USA
Olalekan Oluwole, Susan Greenhut, Bipin N. Savani, and Nishitha Reddy
97. Leukemia Surveillance Counterpoint: Japan
Koji Nagafuji
98. Multiple Myeloma
Shilpi Wadhwa, David Y. Johnson, and Frank E. Johnson
99. Multiple Myeloma Surveillance Counterpoint: USA
Niyati Modi, G. David Roodman, and Suzanne Lentzsch
100. Multiple Myeloma Surveillance Counterpoint: Australia
Liane Khoo and Douglas Joshua
101. Multiple Myeloma Surveillance Counterpoint: Japan
Katsuto Takenaka
102. Multiple Myeloma Surveillance Counterpoint: Canada
Matthew C. Cheung and Kevin R. Imrie
103. Glioma of the Central Nervous System
David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson
104. Glioma of the Central Nervous System Surveillance Counterpoint: Europe
Wolfgang Grisold, Stefan Oberndorfer, and Eefje Sizoo
105. Glioma of the Central Nervous System Surveillance Counterpoint: Australia
Margot Lehman and Michael Barton
106. Glioma of the Central Nervous System Surveillance Counterpoint: Japan
Masahiro Mizoguchi, Koji Yoshimoto, and Tomio Sasaki
Show morePatient Surveillance After Cancer Treatment covers the history of cancer patient surveillance after curative-intent treatment, the rationale, the methodologies used in the past and at present, the methodologies that will probably emerge in the future, the costs of surveillance, the definitions of various terms used in the field, and how those who are interested in the topic can get more information about it from the internet. The secondary focus of the book is to publicize the need for well-designed, adequately powered randomized clinical trials comparing two (or more) surveillance strategies for each type of cancer.
The audience includes all oncologists, cancer researchers, medical economists and policy makers in government and insurance companies, and finally, interested patients.
This book is part of the Current Clinical Oncology series, which provides cutting-edge knowledge of cancer diagnosis, management, and treatment. World renowned experts share their insights in all the major fields of clinical oncology. From the fundamentals of pathophysiology to the latest developments in experimental and novel therapies, Current Clinical Oncology is an indispensable resource for today's practicing oncologist.
Dr. Frank E. Johnson, MD
1. Overview
David Y. Johnson and Frank E. Johnson
2. Introduction to Cancer Surveillance Strategies
Brooke Crawford and David D. Greenberg
3. Using Decision Analysis to Model Cancer Surveillance
Kim E.M. van Kessel, Sandra M.E. Geurts, André L.M. Verbeek, and Ewout W. Steyerberg
4. Cancer Survivorship: Monitoring the Long-Term and Late Effects of Treatment
Craig C. Earle and Jennifer Deevy
5. Upper Aerodigestive Tract Carcinoma
David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson
6. Upper Aerodigestive Tract Carcinoma Surveillance Counterpoint: Europe
Béatrix Barry and Dominique De Raucourt
7. Upper Aerodigestive Tract Carcinoma Surveillance Counterpoint: Japan
Torahiko Nakashima, Ryuji Yasumatsu, and Shizuo Komune
8. Upper Aerodigestive Tract Carcinoma Surveillance Counterpoint: Canada
Richard W. Nason and James B. Butler
9. Thyroid (Papillary, Follicular, Medullary, Hürthle Cell) Carcinoma
David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson
10. Thyroid (Papillary, Follicular, Medullary, Hürthle Cell) Carcinoma Surveillance Counterpoint: Australia
Leigh Delbridge
11. Thyroid (Papillary, Follicular, Medullary, Hürthle Cell) Carcinoma Surveillance Counterpoint: Japan
Ryuji Yasumatsu, Torahiko Nakashima, and Shizuo Komune
12. Lung Carcinoma
Shilpi Wadhwa, David Y. Johnson, and Frank E. Johnson
13. Lung Carcinoma Surveillance Counterpoint: Australia
Michael Boyer and Kate Mahon
14. Lung Carcinoma Surveillance Counterpoint: Japan
Tokujiro Yano and Yoshihiko Maehara
15. Lung Carcinoma Surveillance Counterpoint: Canada
Gail Darling, Yee Ung, Peter Ellis, Lorraine Martelli-Reid, and Bill Evans
16. Esophagus Carcinoma
Shilpi Wadhwa, David Y. Johnson, and Frank E. Johnson
17. Esophagus Carcinoma Surveillance Counterpoint: Australia
Bernard Mark Smithers, Janine M. Thomas, and Bryan H. Burmeister
18. Esophagus Carcinoma Surveillance Counterpoint: Japan
Masaru Morita and Yoshihiko Maehara
19. Stomach
Shilpi Wadhwa, David Y. Johnson, and Frank E. Johnson
20. Stomach Carcinoma Surveillance Counterpoint: USA
Andrew Coleman and Douglas Tyler
21. Stomach Carcinoma Surveillance Counterpoint: Japan
Yoshihiro Kakeji, Masaru Morita, and Yoshihiko Maehara
22. Pancreatic Adenocarcinoma
David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson
23. Pancreatic Adenocarcinoma Surveillance Counterpoint: USA
Tanios S. Bekaii-Saab
24. Pancreatic Adenocarcinoma Surveillance Counterpoint: Europe
Richard A. Smith, Jane V. Butler, and John P. Neoptolemos
25. Pancreatic Adenocarcinoma Surveillance Counterpoint: Japan
Ken Shirabe and Yoshihiko Maehara
26. Pancreatic Adenocarcinoma Surveillance Counterpoint: Canada
Malcolm J. Moore and Anastasios Stathis
27. Liver and Biliary Tract Carcinoma
David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson
28. Liver and Biliary Tract Carcinoma Surveillance Counterpoint: Europe
Michele Colledan
29. Liver and Biliary Tract Carcinoma Surveillance Counterpoint: Australia
Michael D. Crawford
30. Liver and Biliary Tract Carcinoma Surveillance Counterpoint: Japan
Akinobu Taketomi and Yoshihiko Maehara
31. Liver and Biliary Tract Carcinoma Surveillance Counterpoint: Canada
Oliver F. Bathe and Kelly Warren Burak
32. Colon and Rectum Carcinoma
David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson
33. Colon and Rectum Carcinoma Surveillance Counterpoint: USA
Mohamedtaki A. Tejani and Steven J. Cohen
34. Colon and Rectum Carcinoma Surveillance Counterpoint: Australia
Toufic El-Khoury, Michael Solomon, and Jane Young
35. Colon and Rectum Carcinoma Surveillance Counterpoint: Japan
Yasushi Toh and Yoshihisa Sakaguchi
36. Colon and Rectum Carcinoma Surveillance Counterpoint: Canada
Marko Simunovic
37. Anal Carcinoma
David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson
38. Anal Carcinoma Surveillance Counterpoint: USA
Jonathan M. Hernandez, Erin M. Siegel, Abby Koch, and David Shibata
39. Anal Carcinoma Surveillance Counterpoint: Australia
Toufic El-Khoury, Michael Solomon, and Jane Young
40. Anal Carcinoma Surveillance Counterpoint: Japan
Yoshihisa Sakaguchi and Yasushi Toh
41. Anal Carcinoma Surveillance Counterpoint: Canada
Natasha Press and John Hay
42. Soft Tissue Sarcoma
David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson
43. Soft Tissue Sarcoma Surveillance Counterpoint: USA
Valeriy Sedov and Janice M. Mehnert
44. Soft-Tissue Sarcoma Surveillance Counterpoint: Japan
Shuichi Matsuda and Yukihide Iwamoto
45. Soft Tissue Sarcoma Surveillance Counterpoint: Canada
Lloyd A. Mack and Vivien H.C. Bramwell
46. Osteogenic Sarcoma and Dedifferentiated Chondrosarcoma
David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson
47. Osteogenic Sarcoma and Dedifferentiated Chondrosarcoma Surveillance Counterpoint: Japan
Shuichi Matsuda and Yukihide Iwamoto
48. Osteogenic Sarcoma and Dedifferentiated Chondrosarcoma Surveillance Counterpoint: Canada
Timothy R. Asmis, Joel Werier, and Shailendra Verma
49. Cutaneous Melanoma
David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson
50. Cutaneous Melanoma Surveillance Counterpoint: USA
Gerald Linette and Lynn A. Cornelius
51. Cutaneous Melanoma Surveillance Counterpoint: Australia
Michael A. Henderson
52. Cutaneous Melanoma Surveillance Counterpoint: Japan
Yoichi Moroi
53. Breast Carcinoma
David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson
54. Breast Carcinoma Surveillance Counterpoint: USA
Kelli Pettit and Julie A. Margenthaler
55. Breast Carcinoma Surveillance Counterpoint: Europe
Stefano Ciatto
56. Breast Carcinoma Surveillance Counterpoint: Australia
Andrew J. Spillane and Meagan E. Brennan
57. Breast Carcinoma Surveillance Counterpoint: Japan
Eriko Tokunaga and Yoshihiko Maehara
58. Endometrial Carcinoma
David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson
59. Endometrial Cancer Surveillance Counterpoint: USA
Amit Bhate, Eric Donnelly, John Lurain, Julian Schink, and William Small Jr.
60. Endometrial Cancer Surveillance Counterpoint: USA
Summer B. Dewdney and Premal H. Thaker
61. Carcinoma of the Endometrium Surveillance Counterpoint: Japan
Yousuke Ueoka, Hiroaki Kobayashi, and Norio Wake
62. Endometrial Carcinoma Surveillance Counterpoint: Canada
Michael Fung-Kee-Fung and Thomas K. Oliver
63. Cervical Carcinoma
David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson
64. Cervical Carcinoma Surveillance Counterpoint: USA
Joshua P. Kesterson and Shashikant Lele
65. Cervical Carcinoma Surveillance Counterpoint: Japan
Kenzo Sonoda, Hiroaki Kobayashi, and Norio Wake
66. Cervical Carcinoma Surveillance Counterpoint: Canada
Michael Fung-Kee-Fung and Thomas K. Oliver
67. Vaginal and Vulvar Carcinoma
David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson
68. Vaginal and Vulvar Carcinoma Surveillance Counterpoint: Japan
Shinji Ogawa, Hiroaki Kobayashi, and Norio Wake
69. Ovarian Carcinoma
David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson
70. Ovarian Carcinoma Surveillance Counterpoint: USA
Maurie Markman
71. Ovarian Cancer Surveillance Counterpoint: Europe
Andy Nordin
72. Ovarian Cancer Surveillance Counterpoint: Japan
Hiroaki Kobayashi and Norio Wake
73. Renal Carcinoma
Shilpi Wadhwa, David Y. Johnson, and Frank E. Johnson
74. Renal Carcinoma Surveillance Counterpoint: Europe
Alessandro Antonelli, Claudio Simeone, and Sergio Cosciani Cunico
75. Renal Carcinoma Surveillance Counterpoint: Japan
Masatoshi Eto, Wataru Takahashi, Yoshiaki Kawano, Jiro Honda, Juro Nakanishi, and Yoshihiro Wada
76. Renal Carcinoma Surveillance Counterpoint: Canada
Michael Leveridge, Robert Abouassaly, and Michael A.S. Jewett
77. Urinary Bladder Carcinoma
David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson
78. Urinary Bladder Carcinoma Surveillance Counterpoint: Japan
Kentaro Kuroiwa
79. Urinary Bladder Carcinoma Surveillance Counterpoint: Canada
Faysal A. Yafi and Wassim Kassouf
80. Prostate Carcinoma
David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson
81. Prostate Carcinoma Surveillance Counterpoint: USA
Angela Smith and Raj Pruthi
82. Prostate Carcinoma Surveillance Counterpoint: USA
Erik T. Goluboff and Matthew Wosnitzer
83. Prostate Carcinoma Surveillance Counterpoint: Europe
Stefano Ciatto
84. Prostate Carcinoma Surveillance Counterpoint: Japan
Akira Yokomizo
85. Prostate Carcinoma Surveillance Counterpoint: Canada
Andrew Loblaw and Colin Tang
86. Testicle Carcinoma
David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson
87. Testicle Carcinoma Surveillance Counterpoint: USA
Ian M. Thompson III and Sam S. Chang
88. Testicle Carcinoma Surveillance Counterpoint: Australia
Michael Boyer and Kate Mahon
89. Testicle Carcinoma Surveillance Counterpoint: Japan
Narihito Seki
90. Lymphoma
David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson
91. Lymphoma Surveillance Counterpoint: USA
Kenneth R. Carson and Nancy L. Bartlett
92. Lymphoma Surveillance Counterpoint: Japan
Kenjiro Kamezaki
93. Lymphoma (Following Autologous Stem Cell Transplant)
Shilpi Wadhwa, David Y. Johnson, and Frank E. Johnson
94. Lymphoma (Following Autologous Stem Cell Transplant) Surveillance Counterpoint: Japan
Toshihiro Miyamoto
95. Leukemia
David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson
96. Leukemia Surveillance Counterpoint: USA
Olalekan Oluwole, Susan Greenhut, Bipin N. Savani, and Nishitha Reddy
97. Leukemia Surveillance Counterpoint: Japan
Koji Nagafuji
98. Multiple Myeloma
Shilpi Wadhwa, David Y. Johnson, and Frank E. Johnson
99. Multiple Myeloma Surveillance Counterpoint: USA
Niyati Modi, G. David Roodman, and Suzanne Lentzsch
100. Multiple Myeloma Surveillance Counterpoint: Australia
Liane Khoo and Douglas Joshua
101. Multiple Myeloma Surveillance Counterpoint: Japan
Katsuto Takenaka
102. Multiple Myeloma Surveillance Counterpoint: Canada
Matthew C. Cheung and Kevin R. Imrie
103. Glioma of the Central Nervous System
David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson
104. Glioma of the Central Nervous System Surveillance Counterpoint: Europe
Wolfgang Grisold, Stefan Oberndorfer, and Eefje Sizoo
105. Glioma of the Central Nervous System Surveillance Counterpoint: Australia
Margot Lehman and Michael Barton
106. Glioma of the Central Nervous System Surveillance Counterpoint: Japan
Masahiro Mizoguchi, Koji Yoshimoto, and Tomio Sasaki
Show more1. Overview.- 2. Introduction to Cancer Surveillance Strategies.- 3. Using Decision Analysis to Model Cancer Surveillance.- 4. Cancer Survivorship: Monitoring the Long-Term and Late Effects of Treatment.- 5. Upper Aerodigestive Tract Carcinoma.- 6. Upper Aerodigestive Tract Carcinoma Surveillance Counterpoint: Europe.- 7. Upper Aerodigestive Tract Carcinoma Surveillance Counterpoint: Japan.- 8. Upper Aerodigestive Tract Carcinoma Surveillance Counterpoint: Canada.- 9. Thyroid (Papillary, Follicular, Medullary, Hürthle Cell) Carcinoma.- 10. Thyroid (Papillary, Follicular, Medullary, Hürthle Cell) Carcinoma Surveillance Counterpoint: Australia.- 11. Thyroid (Papillary, Follicular, Medullary, Hürthle Cell) Carcinoma Surveillance Counterpoint: Japan.- 12. Lung Carcinoma.- 13. Lung Carcinoma Surveillance Counterpoint: Australia.- 14. Lung Carcinoma Surveillance Counterpoint: Japan.- 15. Lung Carcinoma Surveillance Counterpoint: Canada.- 16. Esophagus Carcinoma.- 17. Esophagus Carcinoma Surveillance Counterpoint: Australia.- 18. Esophagus Carcinoma Surveillance Counterpoint: Japan.- 19. Stomach.- 20. Stomach Carcinoma Surveillance Counterpoint: USA.- 21. Stomach Carcinoma Surveillance Counterpoint: Japan.- 22. Pancreatic Adenocarcinoma.- 23. Pancreatic Adenocarcinoma Surveillance Counterpoint: USA.- 24. Pancreatic Adenocarcinoma Surveillance Counterpoint: Europe.- 25. Pancreatic Adenocarcinoma Surveillance Counterpoint: Japan.- 26. Pancreatic Adenocarcinoma Surveillance Counterpoint: Canada.- 27. Liver and Biliary Tract Carcinoma.- 28. Liver and Biliary Tract Carcinoma Surveillance Counterpoint: Europe.- 29. Liver and Biliary Tract Carcinoma Surveillance Counterpoint: Australia.- 30. Liver and Biliary Tract Carcinoma Surveillance Counterpoint: Japan.- 31. Liver and Biliary Tract Carcinoma Surveillance Counterpoint: Canada.- 32. Colon and Rectum Carcinoma.- 33. Colon and Rectum Carcinoma Surveillance Counterpoint: USA.- 34. Colon and RectumCarcinoma Surveillance Counterpoint: Australia.- 35. Colon and Rectum Carcinoma Surveillance Counterpoint: Japan.- 36. Colon and Rectum Carcinoma Surveillance Counterpoint: Canada.- 37. Anal Carcinoma.- 38. Anal Carcinoma Surveillance Counterpoint: USA.- 39. Anal Carcinoma Surveillance Counterpoint: Australia.- 40. Anal Carcinoma Surveillance Counterpoint: Japan.- 41. Anal Carcinoma Surveillance Counterpoint: Canada.- 42. Soft Tissue Sarcoma.- 43. Soft Tissue Sarcoma Surveillance Counterpoint: USA.- 44. Soft-Tissue Sarcoma Surveillance Counterpoint: Japan.- 45. Soft Tissue Sarcoma Surveillance Counterpoint: Canada.- 46. Osteogenic Sarcoma and Dedifferentiated Chondrosarcoma.- 47. Osteogenic Sarcoma and Dedifferentiated Chondrosarcoma Surveillance Counterpoint: Japan.- 48. Osteogenic Sarcoma and Dedifferentiated Chondrosarcoma Surveillance Counterpoint: Canada.- 49. Cutaneous Melanoma.- 50. Cutaneous Melanoma Surveillance Counterpoint: USA.- 51. Cutaneous Melanoma Surveillance Counterpoint: Australia.- 52. Cutaneous Melanoma Surveillance Counterpoint: Japan.- 53. Breast Carcinoma.- 54. Breast Carcinoma Surveillance Counterpoint: USA.- 55. Breast Carcinoma Surveillance Counterpoint: Europe.- 56. Breast Carcinoma Surveillance Counterpoint: Australia.- 57. Breast Carcinoma Surveillance Counterpoint: Japan.- 58. Endometrial Carcinoma.- 59. Endometrial Cancer Surveillance Counterpoint: USA.- 60. Endometrial Cancer Surveillance Counterpoint: USA.- 61. Carcinoma of the Endometrium Surveillance Counterpoint: Japan.- 62. Endometrial Carcinoma Surveillance Counterpoint: Canada.- 63. Cervical Carcinoma.- 64. Cervical Carcinoma Surveillance Counterpoint: USA.- 65. Cervical Carcinoma Surveillance Counterpoint: Japan.- 66. Cervical Carcinoma Surveillance Counterpoint: Canada.- 67. Vaginal and Vulvar Carcinoma.- 68. Vaginal and Vulvar Carcinoma Surveillance Counterpoint: Japan.- 69. Ovarian Carcinoma.- 70. Ovarian Carcinoma Surveillance Counterpoint:USA.- 71. Ovarian Cancer Surveillance Counterpoint: Europe.- 72. Ovarian Cancer Surveillance Counterpoint: Japan.- 73. Renal Carcinoma.- 74. Renal Carcinoma Surveillance Counterpoint: Europe.- 75. Renal Carcinoma Surveillance Counterpoint: Japan.- 76. Renal Carcinoma Surveillance Counterpoint: Canada.- 77. Urinary Bladder Carcinoma.- 78. Urinary Bladder Carcinoma Surveillance Counterpoint: Japan.- 79. Urinary Bladder Carcinoma Surveillance Counterpoint: Canada.- 80. Prostate Carcinoma.- 81. Prostate Carcinoma Surveillance Counterpoint: USA.- 82. Prostate Carcinoma Surveillance Counterpoint: USA.- 83. Prostate Carcinoma Surveillance Counterpoint: Europe.- 84. Prostate Carcinoma Surveillance Counterpoint: Japan.- 85. Prostate Carcinoma Surveillance Counterpoint: Canada.- 86. Testicle Carcinoma.- 87. Testicle Carcinoma Surveillance Counterpoint: USA.- 88. Testicle Carcinoma Surveillance Counterpoint: Australia.- 89. Testicle Carcinoma Surveillance Counterpoint: Japan.- 90. Lymphoma.- 91. Lymphoma Surveillance Counterpoint: USA.- 92. Lymphoma Surveillance Counterpoint: Japan.- 93. Lymphoma (Following Autologous Stem Cell Transplant).- 94. Lymphoma (Following Autologous Stem Cell Transplant) Surveillance Counterpoint: Japan.- 95. Leukemia.- 96. Leukemia Surveillance Counterpoint: USA.- 97. Leukemia Surveillance Counterpoint: Japan.- 98. Multiple Myeloma.- 99. Multiple Myeloma Surveillance Counterpoint: USA.- 100. Multiple Myeloma Surveillance Counterpoint: Australia.- 101. Multiple Myeloma Surveillance Counterpoint: Japan.- 102. Multiple Myeloma Surveillance Counterpoint: Canada.- 103. Glioma of the Central Nervous System.- 104. Glioma of the Central Nervous System Surveillance Counterpoint: Europe.- 105. Glioma of the Central Nervous System Surveillance Counterpoint: Australia.- 106. Glioma of the Central Nervous System Surveillance Counterpoint:Japan.
Dr. Frank E. Johnson, MD
From the reviews:“This book discusses surveillance strategies for patients completing curative-intent primary treatment for cancer. … Members of the oncology treatment team as well as primary care health professionals who provide post-treatment follow-up survivorship care will benefit from this informative, disease-specific resource. … This is an extremely valuable and useful compilation of cancer site-specific surveillance guidelines for follow-up of asymptomatic patients who have completed primary treatment with curative intent.” (Judith G. Abramson, Doody’s Book Reviews, September, 2013)“Patient Surveillance After Cancer Treatment is a well-written, well-organized reference designed to speak to any practicing oncologist or primary care provider that follows cancer patients after treatment for curative intent. … This is a great text and reference to any clinically practicing oncologist, primary care provider, survivorship program, and training physician of any level. Patient Surveillance After Cancer Treatment will continue to prove itself useful and will be readily available in our library.” (Nima Nabavizadeh and David Elliott, Journal of Radiation Oncology, Vol. 2 (3), September, 2013)
 |
Ask a Question About this Product More... |
|
